Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study.

[1]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[2]  Maya B. Mathur,et al.  Commentary: Developing best-practice guidelines for the reporting of E-values , 2020, International journal of epidemiology.

[3]  Charles E. Leonard,et al.  Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016 , 2020, JAMA network open.

[4]  J. Coresh,et al.  Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. , 2020, JAMA internal medicine.

[5]  A. Garg,et al.  Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. , 2019, JAMA.

[6]  S. George,et al.  Association of Early Physical Therapy With Long-term Opioid Use Among Opioid-Naive Patients With Musculoskeletal Pain , 2018, JAMA network open.

[7]  Olaf Klungel,et al.  The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) , 2018, British Medical Journal.

[8]  J. Coresh,et al.  Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[9]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[10]  K. Huybrechts,et al.  Evaluation of algorithms to identify delirium in administrative claims and drug utilization database , 2017, Pharmacoepidemiology and drug safety.

[11]  S. Minozzi,et al.  Baclofen for alcohol use disorder. , 2017, The Cochrane database of systematic reviews.

[12]  Z. Massy,et al.  Neurological complications in chronic kidney disease patients. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[14]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[15]  D. Solomon,et al.  Active-comparator design and new-user design in observational studies , 2015, Nature Reviews Rheumatology.

[16]  K. Dalhoff,et al.  A Nationwide Register‐Based Survey of Baclofen Toxicity , 2015, Basic & clinical pharmacology & toxicology.

[17]  E. Shink,et al.  Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations , 2014, Journal of clinical pharmacology.

[18]  M. Lipsitch,et al.  Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.

[19]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[20]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Bulletin of the World Health Organization.

[21]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[22]  Matthew H Samore,et al.  Risk Factors for Adverse Drug Events: A 10-Year Analysis , 2005, The Annals of pharmacotherapy.

[23]  R. Hirsch,et al.  Skeletal Muscle Relaxant Use in the United States: Data From the Third National Health and Nutrition Examination Survey (NHANES III) , 2004, Spine.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  G. Tomei,et al.  A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity , 2004, Drug safety.

[26]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.